Physician profile
Anna E Marshall
NPI 1821330291
$540.35
in general payments reported to CMS, 2019-2025
16 companies · $88.51 in 2025
The $88.51 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.03 · 2023: $64.66 · 2024: $297 · 2025: $88.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $88.51 | 2025 | |
| Ethicon US, LLC | $55.86 | 2021 | |
| Mdd US Operations, LLC | $54.39 | 2024 | Gocovri |
| Ucb, INC. | $44.85 | 2024 | Briviact |
| Medtronic, INC. | $41.99 | 2023 | Intellis Adaptivestim |
| Averitas Pharma INC. | $41.65 | 2024 | Qutenza |
| Grifols USA, LLC | $34.37 | 2024 | Gamunex-C |
| Banner Life Sciences, LLC | $26.81 | 2024 | |
| Abbott Laboratories | $22.67 | 2023 | Eterna |
| Neurelis, INC. | $22.58 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $21.89 | 2024 | Austedo Xr |
| Depuy Synthes Sales INC. | $21.40 | 2021 | |
| Amgen INC. | $18.27 | 2024 | Uplizna |
| Abbvie INC. | $16.42 | 2024 | |
| Jazz Pharmaceuticals INC. | $15.92 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.